WallStSmart

Advanced Biomed Inc. Common Stock (ADVB)vsIDEXX Laboratories Inc (IDXX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IDXX leads profitability with a 25.0% profit margin vs 0.0%. ADVB trades at a lower P/E of 2.1x. IDXX earns a higher WallStSmart Score of 63/100 (C+).

ADVB

Avoid

33

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 6.7Quality: 7.8
Piotroski: 4/9

IDXX

Buy

63

out of 100

Grade: C+

Growth: 6.7Profit: 10.0Value: 2.7Quality: 7.0
Piotroski: 6/9Altman Z: 5.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ADVB.

IDXXSignificantly Overvalued (-48.7%)

Margin of Safety

-48.7%

Fair Value

$436.26

Current Price

$509.56

$73.30 premium

UndervaluedFair: $436.26Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ADVB3 strengths · Avg: 10.0/10
P/E RatioValuation
2.1x10/10

Attractively priced relative to earnings

Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

IDXX4 strengths · Avg: 9.8/10
Return on EquityProfitability
70.7%10/10

Every $100 of equity generates 71 in profit

Operating MarginProfitability
35.0%10/10

Strong operational efficiency at 35.0%

Altman Z-ScoreHealth
5.9210/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
25.0%9/10

Keeps 25 of every $100 in revenue as profit

Areas to Watch

ADVB4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$14.62M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

IDXX3 concerns · Avg: 2.7/10
P/E RatioValuation
36.5x4/10

Premium valuation, high expectations priced in

PEG RatioValuation
2.932/10

Expensive relative to growth rate

Price/BookValuation
24.9x2/10

Trading at 24.9x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : ADVB

The strongest argument for ADVB centers on P/E Ratio, Price/Book, Debt/Equity.

Bull Case : IDXX

The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 25.0% and operating margin at 35.0%.

Bear Case : ADVB

The primary concerns for ADVB are Revenue Growth, EPS Growth, Market Cap.

Bear Case : IDXX

The primary concerns for IDXX are P/E Ratio, PEG Ratio, Price/Book.

Key Dynamics to Monitor

ADVB profiles as a value stock while IDXX is a mature play — different risk/reward profiles.

IDXX is growing revenue faster at 9.7% — sustainability is the question.

IDXX generates stronger free cash flow (323M), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

IDXX scores higher overall (63/100 vs 33/100), backed by strong 25.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Advanced Biomed Inc. Common Stock

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. The company is headquartered in New York, New York.

IDEXX Laboratories Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.

Want to dig deeper into these stocks?